Skip to main
ESLA
ESLA logo

ESLA Stock Forecast & Price Target

ESLA Analyst Ratings

Based on 1 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Estrella Immunopharma is advancing its EB104 dual CD19/CD22 program, with promising initial results supporting a higher dose cohort, indicating strong safety and efficacy metrics that enhance its competitive stance in T-cell therapies. The company's strategic focus on potential partnerships aims to broaden its reach across B-cell malignancies and autoimmune diseases, which could substantially expand its market presence as it progresses through 2025. Moreover, Estrella's innovative Artemis Technology platform positions the company to access new market opportunities in immunology, particularly in addressing solid tumors, which is widely regarded as a significant breakthrough in CAR-T therapy.

Bears say

Estrella Immunopharma faces significant market challenges as evidenced by the recurring data on the potential treatment of relapsed/refractory B-cell Non-Hodgkin’s Lymphomas in China, which shows incremental growth in addressable patient populations but lacks demonstrable commercial viability or successful product launches. The company’s reliance on its CD19 and CD22-targeted ARTEMIS T-cell therapies raises concerns regarding their efficacy and approval timelines, which could impact future revenue streams. Furthermore, the overall competitive landscape within the biopharmaceutical sector, particularly for blood cancers, places added pressure on Estrella's market position and financial outlook.

ESLA has been analyzed by 1 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Estrella Immunopharma Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Estrella Immunopharma Inc (ESLA) Forecast

Analysts have given ESLA a Strong Buy based on their latest research and market trends.

According to 1 analysts, ESLA has a Strong Buy consensus rating as of Nov 26, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $16, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $16, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Estrella Immunopharma Inc (ESLA)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.